366 related articles for article (PubMed ID: 29946818)
1. Effect of frequency of intravenous iron administration on hemoglobin variability in maintenance hemodialysis patients.
Wan L; Zhang D
Int Urol Nephrol; 2018 Aug; 50(8):1511-1518. PubMed ID: 29946818
[TBL] [Abstract][Full Text] [Related]
2. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
3. [Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study].
Li H; Wang SX
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):457-62. PubMed ID: 19567093
[TBL] [Abstract][Full Text] [Related]
4. [Opatija study: observation of hemodialysis patients and titration of CERA dose just switched from another erythropoiesis stimulating agent].
Jelić I; Lovcić V; Kurtović I; Josipović M; Havranek Z; Kostić L; Racki S
Acta Med Croatica; 2012 Jul; 66(3):157-64. PubMed ID: 23441529
[TBL] [Abstract][Full Text] [Related]
5. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
6. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration.
Herrera J; Nava M; Romero F; Rodríguez-Iturbe B
Am J Kidney Dis; 2001 Apr; 37(4):750-7. PubMed ID: 11273875
[TBL] [Abstract][Full Text] [Related]
7. Effect of protoconized therapy for renal anemia on adverse events of patients with maintenance hemodialysis.
Kuragano T; Yahiro M; Kida A; Furuta M; Nagasawa Y; Hasuike Y; Nanami M; Nakanishi T
Int J Artif Organs; 2014 Dec; 37(12):865-74. PubMed ID: 25450320
[TBL] [Abstract][Full Text] [Related]
8. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
[TBL] [Abstract][Full Text] [Related]
9. [Multi-frequency low-dose intravenous iron on oxidative stress in maintenance hemodialysis patients].
Yin L; Chen X; Chen J; Cheng M; Peng Y; Yang L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Aug; 37(8):844-8. PubMed ID: 22954919
[TBL] [Abstract][Full Text] [Related]
10. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
11. Continuous intravenous sodium ferric gluconate improves efficacy in the maintenance phase of EPOrHu administration in hemodialysis patients.
Bolaños L; Castro P; Falcón TG; Mouzo R; Varela JM
Am J Nephrol; 2002; 22(1):67-72. PubMed ID: 11919405
[TBL] [Abstract][Full Text] [Related]
12. Intercurrent events and comorbid conditions influence hemoglobin level variability in dialysis patients.
DeFrancisco AL; Macdougall IC; Carrera F; Braun J; Bárány P; Bridges I; Wheeler T; Tran D; Dietrich A
Clin Nephrol; 2009 Apr; 71(4):397-404. PubMed ID: 19356372
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients.
Nissenson AR; Berns JS; Sakiewicz P; Ghaddar S; Moore GM; Schleicher RB; Seligman PA
Am J Kidney Dis; 2003 Aug; 42(2):325-30. PubMed ID: 12900815
[TBL] [Abstract][Full Text] [Related]
14. Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload.
Lin CL; Hsu PY; Yang HY; Huang CC
Ren Fail; 2003 May; 25(3):445-53. PubMed ID: 12803508
[TBL] [Abstract][Full Text] [Related]
15. Multifactorial analysis of renal anemia-associated substandard hemoglobin levels and prevalence of anemia in patients on maintenance hemodialysis in Liaoning Province: a cross-sectional study.
Yin S; Du Y; Guo Y; Guo G; Sun D; Yao L
Ann Palliat Med; 2022 Dec; 11(12):3743-3754. PubMed ID: 36635999
[TBL] [Abstract][Full Text] [Related]
16. [The use of erythropoietin beta, two to three times per week, once per week and once every other week: meta-analysis of two clinical trials].
Pljesa S
Med Pregl; 2007; 60(3-4):123-7. PubMed ID: 17853722
[TBL] [Abstract][Full Text] [Related]
17. Comparison of two iron gluconate treatment modalities in chronic hemodialysis patients: results of a randomized trial.
Giordano A; Arrigo G; Lavarda F; Colasanti G; Petrini C
J Nephrol; 2005; 18(2):181-7. PubMed ID: 15931646
[TBL] [Abstract][Full Text] [Related]
18. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa.
Chazot C; Terrat JC; Dumoulin A; Ang KS; Gassia JP; Chedid K; Maurice F; Canaud B;
Ann Pharmacother; 2009 Feb; 43(2):228-34. PubMed ID: 19407262
[TBL] [Abstract][Full Text] [Related]
19. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
20. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
